08:00-09:00 |
Registration |
09:00 |
Opening Remark |
|
09:00 - 10:30 |
[JS01] KAI-KSH Joint Symposium
- Immunotherapeutics in Blood Disease |
[SS01] Bone Marrow Failure |
|
|
Immune checkpoint inhibitor in cancer
(Seung-Woo Lee, Korea)
CAR-T
(Chan Hyuk Kim, Korea)
Cytotoxic T lymphocyte therapy
(Hyewon Lee, Korea)
Immune checkpoint inhibitor in lymphoma
(Dok Hyun Yoon, Korea) |
TBD
?€ Germ line mutations in inherited BM failure
(Jean Soulier, France)
Telomere length and somatic mutations in aplastic anaemia
(Dong Soon Lee, Korea) |
10:30 - 10:45 |
Coffee Break |
10:45- 11:45 |
Plenary Lecture I - Gene Therapy in Hematology |
|
Application of CRISPR/Cas-9 in blood disease
(Matthew H. Porteus, USA)
Gene therapy for hemophilia
(Katherine High, USA) |
11:45- 12:45 |
Presidential Symposium |
|
Stem cells in AML
(Ravindra Majeti, USA)
Optimal treatment of adolescents and young adult ALL
(Ching-Hon Pui, USA) |
12:45 - 13:40 |
[LS01] |
[LS02] |
[LS03] |
TBD |
TBD |
TBD |
13:40 - 14:40 |
[AS01] Asian Hematology Symposium: Lymphoid |
[AS02] Asian Hematology Symposium: Myeloid |
|
|
NHL in India
(T. Raja, India)
ALL in Taiwan
(Tran-Der Tan, Taiwan)
ALL in Malaysia
(Sen Mui Tan, Malaysia) |
TBD
TBD
Hemoglobinopathy in Thailand
(Suradej Hongeng, Thailand) |
14:40 - 14:55 |
Coffee Break |
14:55 - 16:25 |
[JS02] KOGO-KSH Joint Symposium- Genomics for Precision Hematology |
[SS02] Multiple Myeloma: How is MM Developed and Progressed? From 3 Different Viewpoint |
[SS03] Transplantation/Cell Therapy |
[ES01] Iron Metabolism |
Understanding angioimmunoblastic T-cell lymphoma: from genomics to animal pathology
(Jaesang Kim, Korea)
Genomic pathogenesis of epstein–barr virus (EBV)- induced diffuse large B cell lymphoma
(Sung-Yup Cho, Korea)
Current status of precision hematology
(Young-Uk Cho, Korea)
Clinical application of precision hematology
(Joon-Ho Moon, Korea) |
High risk MM identifyed by genomic analysis
(Gareth Morgan, UK)
What role does bone marrow microenvironment play on MM cells
(Yusuke Furukawa, Japan)
Antigen-mediated regulation in MM
(Madhav Dhodapkar, USA) |
TK cell therapy
(Chiara Bonini, Italy)
Updates on CAR T cell therapy for
relapsed/refracoty MM
(Jesús Berdeja, USA)
New insights into cancer vaccine strategies
(Larry Kwak, USA) |
Iron metabolism in hemoglobinopathies
(Vip Viprakasit, Thailand)
Deferasirox for iron overload patients: preserving organ functions
(Norbert Gattermann, Germany)
Managing side effects in iron chelation therapy
(Heather Leitch, Canada) |
16:25 - 16:40 |
Break |
16:40 - 18:10 |
[SS04] Myeloproliferative Neoplasm |
[SS05] Bleeding Disorder/Thrombosis |
[SS06] Pediatric Disease: Inherited hematologic malignancies |
[ES02] Indolent Lymphoma: From Genetics to the Clinic |
Clinical significance of genetic stratification of MPN patients
(Robert Kralovics , Austria)
Molecular mechanism of MPN development by mutant calreticulin
(Norio Komatsu, Japan)
Interferon treatment for MPN
(Jean-Jacques Kiladjian, France) |
Gene therapy for hemophilia
(Glenn F. Pierce, USA)
Individualized treatment for hemophilia : population pharmacokinetics approach
(Cindy Yeung, Canada)
Mechanisms of cancer-associated thrombosis
(Nigel Mackman, USA) |
Inherited hematologic malignancies
(Lucy Godley, USA)
GATA2 leukemogenesis
(Jean Donadieu, France)
Roles of monosomy 7 and SAMD9/SAMD9L mutations in myeloid leukemogenesis
(Hirotaka Matsui, Japan) |
Mantle cell lymphoma
(Mats Jerkeman, Sweden)
Follicular lymphoma
(Gilles Salles , France)
Chronic lymphocytic leukemia/ small lymphocytic lymphoma
(Wei Xu, China) |
18:10 - 18:30 |
Break |
18:30 - 20:00 |
Welcome Reception |